Operator
Welcome to the Q1 2021 Intercept Pharmaceuticals Earnings Call. My name is Anette, and I ll be your operator for today s call. [Operator Instructions]
I will now turn the call over to Lisa DeFrancesco. Lisa, you may begin.
Lisa DeFrancesco
Senior Vice President of Investor Relations and Corporate Affairs
Thank you. Good morning, and thank you for joining us on today s call. This morning, we issued a press release announcing our first quarter 2021 results and financial position, which is available on our website at www.interceptpharma.com. Before we begin our discussion, I d like to note that during our call, we will be making forward-looking statements, including statements regarding our approved product and clinical development program; certain regulatory matters; and our strategy, prospects, financial guidance and future commercial and financial performance. Listeners are cautioned not to place undue reliance on these forward-looking statements, which speak only as
US gene-editing firm eGenesis closes $125m in Series C round dealstreetasia.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from dealstreetasia.com Daily Mail and Mail on Sunday newspapers.